After disease recurrence, 20 out of 51 (39.2%) patients with HER2-zero primary samples and 19 out of 71 (26.8%) patients with HER2-positive primary breast cancer samples showed a shift to HER2-low status. Here, ERBB2 is linked to breast cancer.